Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Catabasis’s Future In Doubt After DMD Phase III Failure

Executive Summary

Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.

You may also be interested in...



Oncology’s Hold Over The Pharma Pipeline Increases As Growth Slows

The rate of growth of the pharma pipeline slowed last year as oncology and rare diseases tightened their grip on R&D. There are also further signs of China’s rise in importance in the industry.

Vaccines Helped GSK Post Strong Q1 Results Ahead Of RSV Approval

Increased disease awareness and the IRA should help boost the RSV prevention market for older adults, said GSK CEO Emma Walmsley, ahead of a US approval decision early next month, as the firm’s vaccines division helped push a strong Q1 performance. Other deals are also ‘in the hopper.’

10 Approvals To Look Out For In Q2

The second quarter has already seen the approval of Gamida Cell’s cell therapy Omisirge, and with the help of Biomedtracker, Scrip highlights 10 of the more interesting new drug approvals due in the next three months.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC143212

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel